Good MorningEquities reversed course to fall about 0.75% on the first trading day of June. The move was driven by a rising fear of economic catastrophe that was brought into sharp focus by JPMorgan Chase CEO Jamie Dimon. Dimon says the US should get ready for an economic hurricane caused by the Fed and fallout from the Russian invasion of Ukraine. In his view, oil could hit $150 per barrel and drive inflation to new heights.
The chart of the S&P 500 is beginning to show signs of weakness in the rebound. The index hit resistance at the key 4,100 level and right now that resistance is confirmed. If the market can not get over this level the least of what we expect is a retest of support at the 3,900 level. If price action moves below there, and there is no reason now why it won't, we think the broad market could fall another 5% to 10% before hitting the next support zone. Featured: The case for trading fewer setups, not more (Ad) 
|
Technology | |
HP Inc Pops On Results But Gains Are Capped
HP Inc (NYSE: HPQ) shares popped on the Q2 earnings report and are tickling a new all-time high but we aren’t betting on a breakout. While the news is good and the outlook favorable there are some underlying conditions in the market that we see c... Read the Full Story |
|
From Our Partners | | Oracle runs 15,000 stocks through the same filter every single day, scanning for precise setups before the opening bell - no emotion, no guesswork.
Tim Bohen, Lead Trainer at StocksToTrade, is walking through this week's flagged setups and showing exactly how the scanner works in a live training right now. | | Watch the scanner in action and join the live training now |
|
Technology | | Electric vehicle (EV) charging network Blink Charging (NASDAQ: BLNK) stock has fallen (-37%) during the 2022 bear market. The EV charging operator and provider of charging equipment had impressive fiscal Q1 2022 metrics including a 339% increase in revenues and 346% increase in service revenues and ... Read the Full Story |
|
Markets | | Self-care health and wellness products make Perrigo (NASDAQ: PRGO) stock has been recovering well off its $31.22 bottom. The bear market selling seems to have abated as the Company is uniquely positioned to gain during an inflationary cycle as evidenced by its market share gain during the last reces... Read the Full Story |
|
From Our Partners | | Every morning before the market opens, a scanner called Oracle runs through 15,000 stocks and scores the setups — so there's already a plan in place by 6:15 a.m.
Lead Trainer Tim Bohen of StocksToTrade is walking through exactly how Oracle works and how regular traders are using it in a training running right now. | | Watch the Oracle training now and see how the scanner works |
|
Markets | | Beauty products and fragrance maker Coty, Inc. (NYSE: COTY) stock has suffered with the benchmark indices trading down over (-30%) for the year. The Company is the leading fragrance maker with high-end brands including Hugo Boss, Burberry, Mark Jacobs, and Gucci in its portfolio. It also owns the ic... Read the Full Story |
|
Markets | |
Getting payment from dividend stocks quarterly may be one of the reasons that dividend stocks hold some allure for you and your portfolio.
But what exactly are dividend stocks that pay quarterly dividends? How do they work? It's natural to have some of these great questions swirling around in yo... Read the Full Story |
|
From Our Partners | | The U.S. government has taken roughly a 10% stake in Intel, negotiated a 15% cut of Nvidia and AMD chip sales to China, and reportedly received a 5% ownership offer - worth around $40 billion - from the most valuable AI company on earth.
Porter Stansberry calls it the New U.S.A.I. - a state-backed arrangement where Washington and a handful of tech giants are fused at the balance sheet. A small number of companies get pulled inside. Everyone else gets frozen out, including names sitting in your index fund right now. | | Watch the documentary to see which companies are on the right side |
|
Retail/Wholesale | |
The Institutions Like The Price Of Victoria’s Secret & Co
Between the two of them, the analysts and the institutions have put a floor in shares of Victoria’s Secret & Co (NYSE: VSCO). While the Insidertrades.com consensus price target is falling and the institutional activity... Read the Full Story |
|
Technology | |
Ambarella Is A Perfect Fit For Q2 Portfolios
Ambarella’s (NASDAQ: AMBA) shares have been under intense pressure over the past few quarters but we think the bottom is in. The stock price was under pressure due to fears of slowing growth, the impact of the Omicron variant, supply chain issue... Read the Full Story |
|
Markets | |
Salesforce.com’s slowing growth Is priced Into the market
Company lowered its guidance for revenue due to FX headwinds
Stock trades at a high 34X its earnings which is double the average S&P 500
Salesforce.com (NASDAQ: CRM) had a great quarter and is on track to continue growing ... Read the Full Story |
|
Retail/Wholesale | |
The TJX Companies, Inc. (NYSE: TJX) is down 15% this year
DICK’S Sporting Goods, Inc. (NYSE: DKS) is in a slump down 26% year-to-date
Tractor Supply Company (NASDAQ: TSCO) is down 19% this year
Have we reached a breaking point for retail?
Whether defiant or stubborn, American consum... Read the Full Story |
|
Consumer Discretionary | |
Pivotal Research upgraded their rating on Roku, moving it to a Hold from a Sell
Cathie Woods of Ark fame has been among their biggest supporters in recent weeks
Fundamentally, there are reasons to like the stock as well
After falling as much as 85% since last summer, we might be finally st... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California. | | View Today's Stock Pick |
|
